4-[(苯磺酰基)氨基]丁酸 | 85845-09-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-[(苯磺酰基)氨基]丁酸
• 英文名称: 4-<(phenylsulfonyl)amino>butyric acid
• 英文别名: 4-benzenesulfonylamino-butyric acid；γ-Benzolsulfamino-buttersaeure；4-Benzolsulfonylamino-buttersaeure；N-benezenesulfonyl-4-aminobutyric acid；N-benzenesulfonyl gamma-aminobutyric acid；4-[(Phenylsulfonyl)amino]butanoic acid；4-(benzenesulfonamido)butanoic acid
• CAS: 85845-09-6
• 化学式: C₁₀H₁₃NO₄S
• mdl: MFCD00447601
• 分子量: 243.284
• InChiKey: MOGAUQWSGDNMAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2935009090

反应信息

• 作为反应物：
  描述：

  4-[(苯磺酰基)氨基]丁酸 在 二异丁基氢化铝 作用下， 以 正己烷 、 乙酸乙酯 、 甲苯 为溶剂， 反应 0.5h， 生成 1-(phenylsulfonyl)-2-hydroxypyrrolidine
  参考文献：
  名称：

  血栓烷A2受体拮抗剂S-145和相关化合物中分子内氢键的FTIR光谱研究。3.S-145类似物的构象和活性。

  摘要：

  S-145，（+/-）-（5Z）-7- [3-endo-[（苯磺酰基）氨基]双环[2.2.1]庚烯酸，其链类似物HO2C（CH2）nNHSO2Ph（n = 3-8 ，10和11）1-8和（5Z）-9-（苯磺酰基）氨基壬基5-烯酸（9）的合成是为了阐明溶液中的构象和药理活性对侧面的依赖性-链长。在稀释的CCl4溶液中测量其FTIR光谱。对于这些化合物，在羧基和磺酰胺基之间发现了类似于对S-145观察到的分子内氢键。分子内氢键分子的百分数（rho）与n值之间也发现线性关系。在体外检查了化合物1-9对兔和大鼠洗涤的血小板（WP）的U-46619抑制浓度（IC50）和胶原蛋白诱导的聚集，和U-46619诱导的大鼠主动脉收缩。尽管rho值与n值成正比，但三种TXA2受体拮抗效力[log（1 / IC50）]与n值呈抛物线相关性。发现6（n = 8）的log（1 / IC50）值与S-145观察到的类

  DOI：

  10.1021/jm00110a020
• 作为产物：
  描述：

  4-氨基丁酸 生成 4-[(苯磺酰基)氨基]丁酸
  参考文献：
  名称：

  Compounds and compositions for delivering active agents

  摘要：

  本发明提供了具有以下化学式或其盐的化合物，有助于传递活性剂。还提供了包括本发明化合物和至少一种活性剂（如肽、粘多糖、碳水化合物或脂质）的组合物和剂量单位形式。同时还提供了本发明化合物和组合物的给药方法和制备方法。

  公开号：

  US06346242B1

文献信息

• Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions
  申请人：Ralston Stuart Hamilton

  公开号：US20080119555A1

  公开（公告）日：2008-05-22

  The present invention pertains to certain aryl alkyl sulfonamides and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formula: wherein: Ar 1 is independently C 5-20 aryl (e.g., biphenyl, phenanthryl, fluorenyl, or carbazolyl, most preferably biphenyl), and is optionally substituted; R N is independently —H, acyl, C 5-20 aryl-C 1-7 alkyl, C 3-20 heterocyclyl, or C 1-7 alkyl, and is optionally substituted; R alk is a C 2-10 alkylene group, and is optionally substituted; and Q is independently —H or an organic group having from 1 to 30 atoms selected from carbon, nitrogen, oxygen, sulfur, phosphorus, fluorine, chlorine, bromine, and iodine (e.g., an oxy-type group, an amine-type group, etc.); and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit osteoclast survival, formation, and/or activity, and to inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, in the treatment of bone disorders such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, and the like; and/or in the treatment of conditions associated with inflammation or activation of the immune system.

  本发明涉及某些芳基烷基磺酰胺及其衍生物，其中，它们抑制破骨细胞的存活、形成和/或活性；和/或抑制骨吸收，更具体地说，是式子的化合物： 其中：Ar1独立地是C5-20芳基（例如，联苯、菲、芴或咔唑基，最好是联苯），并且可以选择性地被取代；RN独立地是-H、酰基、C5-20芳基-C1-7烷基、C3-20杂环基或C1-7烷基，并且可以选择性地被取代；Ralk是C2-10烷基链，可以选择性地被取代；Q独立地是-H或具有1-30个由碳、氮、氧、硫、磷、氟、氯、溴和碘选择的有机基团（例如，氧型基团，胺型基团等）；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这样的化合物的制药组合物，以及在体外和体内使用这样的化合物和组合物来抑制破骨细胞的存活、形成和/或活性，并抑制由破骨细胞介导和/或通过骨吸收表征的骨疾病的治疗，例如骨质疏松症、类风湿性关节炎、与癌症相关的骨疾病、帕吉特病等；和/或用于治疗与炎症或免疫系统激活有关的疾病。
• Agent for Preventing and Alleviating Wrinkles
  申请人：TSUNENAGA Makoto

  公开号：US20100113450A1

  公开（公告）日：2010-05-06

  The present invention provides an agent for preventing and alleviating wrinkles which has excellent effects of preventing and alleviating wrinkles formed by decreased barrier function of the skin owing to aging or photo aging, that is graphic wrinkles or linear wrinkles. The agent for preventing and alleviating wrinkles consisting of one or more compounds selected from the group consisting of gamma-aminobutyric acid derivatives represented by the following formula (1) or N,N,N-trimethyl gamma-aminobutyric acid represented by the following formula (3) and salts thereof: wherein R 1 and R 2 independently represent any of a hydrogen atom, an alkyl group having 1 to 3 carbon atoms, a benzyloxycarbonyl group, a cyclohexyl group, a cyclohexanemethyl group, a cyclohexanecarbonyl group, a guanidino group formed with nitrogen atom in the formula (1), an ureido group formed with nitrogen atom in the formula (1), and a group represented by following formula (2). Additionally, R 1 and R 2 may jointly form a piperidine ring, morpholine ring, or pyrrolidine ring. Both of R 1 and R 2 are not simultaneously a hydrogen atom.

  本发明提供了一种用于预防和缓解皮肤屏障功能下降引起的老化或光老化形成的皱纹（即图形皱纹或线性皱纹）的药剂。该药剂由以下式（1）所表示的γ-氨基丁酸衍生物或以下式（3）所表示的N，N，N-三甲基γ-氨基丁酸及其盐中的一种或多种化合物组成：其中R1和R2独立地表示氢原子，具有1至3个碳原子的烷基，苄氧羰基基团，环己基基团，环己基甲基基团，环己基羧基基团，在式（1）中的氮原子形成的鸟氨酸基团，在式（1）中的氮原子形成的尿素基团，以及以下式（2）所表示的基团。此外，R1和R2可以共同形成哌啶环，吗啉环或吡咯烷环。R1和R2都不同时为氢原子。
• Agent for alleviating wrinkles
  申请人：Shiseido Company Ltd.

  公开号：US08173705B2

  公开（公告）日：2012-05-08

  The present invention provides an agent for preventing and alleviating wrinkles which has excellent effects of preventing and alleviating wrinkles formed by decreased barrier function of the skin owing to aging or photo aging, that is graphic wrinkles or linear wrinkles. The agent for preventing and alleviating wrinkles consisting of one or more compounds selected from the group consisting of gamma-aminobutyric acid derivatives represented by the following formula (1) or N,N,N-trimethyl gamma-aminobutyric acid represented by the following formula (3) and salts thereof: wherein R1 and R2 independently represent any of a hydrogen atom, an alkyl group having 1 to 3 carbon atoms, a benzyloxycarbonyl group, a cyclohexyl group, a cyclohexanemethyl group, a cyclohexanecarbonyl group, a guanidino group formed with nitrogen atom in the formula (1), an ureido group formed with nitrogen atom in the formula (1), and a group represented by following formula (2). Additionally, R1 and R2 may jointly form a piperidine ring, morpholine ring, or pyrrolidine ring. Both of R1 and R2 are not simultaneously a hydrogen atom.

  本发明提供了一种防止和缓解皱纹的剂，具有优异的防止和缓解因皮肤屏障功能降低而形成的皱纹的效果，即图形皱纹或线性皱纹。该防止和缓解皱纹的剂由以下式（1）表示的γ-氨基丁酸衍生物或以下式（3）表示的N,N,N-三甲基γ-氨基丁酸及其盐中的一种或多种化合物组成：其中，R1和R2独立地表示氢原子、具有1到3个碳原子的烷基、苄氧羰基基团、环己基基团、环己甲基基团、环己基羰基基团、在公式（1）中与氮原子形成的鸟氨酸基团、在公式（1）中与氮原子形成的尿素基团以及以下式（2）所表示的基团中的任意一种。此外，R1和R2可以共同形成哌啶环、吗啉环或吡咯烷环。R1和R2中的任意一个都不是氢原子。
• Use of pyrrolidone derivatives as anti-amnestic agents
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP0288685A2

  公开（公告）日：1988-11-02

  A use of the pyrrolidone derivative represented by the following formula [I] as an anti-amnestic agent: wherein R represents a group X represents -SO₂- or -OC-; Rʹ represents a hydrogen atom, a lower alkyl group, a trifluoromethyl group, a halogen atom or a nitro group; n denotes an integer of 1 - 5; and, when n is an integer of 2 or more, Rʹ may be the same or different,provided that (a) when X is -SO₂-, there is no case where Rʹ is 3-CF₃, 4-Cl-5-CF₃, 3,5-(CF₃)₂ or 3-NO₂; (b) when X is -CO-, there is no case where n denotes 1 or 2 and Rʹ is a halogen atom or a nitro group; (c) when X is -SO₂-, there is no case where n denotes 1 or 2 and Rʹ is a group other than 4-Cl or 3-NO₂; and (d) when n denotes 2, there is no case where the groups Rʹ represents the same group which is a halogen atom or a nitro group. Typial pyrrolidone derivatives are N-(4ʹ-toluene­sulfonyl)-2-pyrrolidone, N-(4ʹ-chlorobenzenesulfonyl)-2-­pyrrolidone, N-benzenesulfonyl-2-pyrrolidone and N-[4ʹ-(1ʺ,1ʺ-­ dimethylethyl)benzoyl]-2-pyrrolidone, particularly N-(4ʹ-chloro­benzenesulfonyl)-2-pyrrolidone.

  由下式[I]代表的吡咯烷酮衍生物作为抗蚜虫剂的用途： 其中 R 代表一个基团 X代表-SO₂-或-OC-； Rʹ代表氢原子、低级烷基、三氟甲基、卤素原子或硝基； n表示1-5的整数；当n为2或2以上的整数时，Rʹ可以相同或不同，条件是 (a) 当 X 为-SO₂- 时，Rʹ 不能是 3-CF₃、4-Cl-5-CF₃、3,5-(CF₃)₂ 或 3-NO₂； (b) 当 X 为-CO-时，不存在 n 表示 1 或 2 且 Rʹ 为卤素原子或硝基的情况； (c) 当 X 为-SO₂- 时，不存在 n 表示 1 或 2 且 Rʹ 为 4-Cl 或 3-NO₂ 以外的基团的情况；以及 (d) 当 n 表示 2 时，不存在基团 Rʹ 代表卤素原子或硝基的情况。 典型的吡咯烷酮衍生物有 N-(4ʹ-甲苯磺酰基)-2-吡咯烷酮、N-(4ʹ-氯苯磺酰基)-2-吡咯烷酮、N-(4ʹ-氯苯磺酰基)-2-吡咯烷酮、N-苯磺酰基-2-吡咯烷酮和 N-[4ʹ-(1ʺ,1ʺ-二甲基乙基)苯甲酰基]-2-吡咯烷酮，特别是 N-(4ʹ-氯苯磺酰基)-2-吡咯烷酮。
• WRINKLING-PREVENTING AND -MODIFYING AGENT
  申请人：Shiseido Company, Ltd.

  公开号：EP2123253A1

  公开（公告）日：2009-11-25

  The present invention provides an agent for preventing and alleviating wrinkles which has excellent effects of preventing and alleviating wrinkles formed by decreased barrier function of the skin owing to aging or photo aging, that is graphic wrinkles or linear wrinkles. The agent for preventing and alleviating wrinkles consisting of one or more compounds selected from the group consisting of gamma-aminobutyric acid derivatives represented by the following formula (1) or N,N,N-trimethyl gamma-aminobutyric acid represented by the following formula (3) and salts thereof: wherein R1 and R2 independently represent any of a hydrogen atom, an alkyl group having 1 to 3 carbon atoms, a benzyloxycarbonyl group, a cyclohexyl group, a cyclohexanemethyl group, a cyclohexanecarbonyl group, a guanidino group formed with nitrogen atom in the formula (1), an ureido group formed with nitrogen atom in the formula (1), and a group represented by following formula (2). Additionally, R1 and R2 may jointly form a piperidine ring, morpholine ring, or pyrrolidine ring. Both of R1 and R2 are not simultaneously a hydrogen atom.

  本发明提供了一种用于预防和减轻皱纹的药剂，该药剂对预防和减轻由于老化或光老化导致皮肤屏障功能降低而形成的皱纹（即图形皱纹或线性皱纹）具有极佳的效果。 这种预防和缓解皱纹的制剂由一种或多种化合物组成，这些化合物选自由下式（1）代表的γ-氨基丁酸衍生物或下式（3）代表的N,N,N-三甲基γ-氨基丁酸及其盐组成的组： 其中，R1 和 R2 独立地代表氢原子、具有 1 至 3 个碳原子的烷基、苄氧羰基、环己基、环己基甲基、环己基羰基、与式（1）中氮原子形成的胍基、与式（1）中氮原子形成的脲基以及下式（2）所代表的基团中的任意一种。此外，R1 和 R2 可共同形成哌啶环、吗啉环或吡咯烷环。R1 和 R2 不能同时为氢原子。